Awakn Life Sciences Completes World’s First Ketamine Treatment Study for a Range of Behavioral Addictions May 19, 2022
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted… May 16, 2022
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in… May 11, 2022
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights May 10, 2022
Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT… Apr 19, 2022
